Business Context and Reporting Period
This Form 8-K Current Report from Altimmune, Inc. (NASDAQ: ALT) is dated November 30, 2025. The filing discloses a significant change in executive leadership and the associated compensatory arrangements. The report details the departure of the current President and Chief Executive Officer (CEO) and the appointment of a successor effective January 1, 2026.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and governance changes.
Material Changes and Executive Transition
- Departure of CEO: Vipin K. Garg, Ph.D., will step down as President and CEO effective January 1, 2026. He will also resign from the Board of Directors effective January 31, 2026.
- Appointment of New CEO: Jerome Durso, currently a Board member and Chairman, has been appointed President and CEO effective January 1, 2026.
- Transition Period: Dr. Garg will serve as an advisor to the Company from January 1, 2026, through June 30, 2026, to assist in the transition of duties.
Compensatory Arrangements and Agreements
Dr. Vipin K. Garg (Outgoing CEO)
Under the Transitional Services and Release Agreement dated November 30, 2025, Dr. Garg is entitled to:
- Continued salary and benefits during the transition period (Jan 1, 2026 – June 30, 2026).
- Severance payments equal to his current base salary for 12 months following the separation date (June 30, 2026).
- A COBRA subsidy for 12 months following the separation date.
- Continued vesting of all outstanding equity awards through the separation date.
- An extension of the exercise period for vested stock options until 18 months after the separation date.
- Eligibility for a full cash bonus for fiscal year 2025, subject to performance criteria and compliance with the agreement.
Mr. Jerome Durso (Incoming CEO)
Under the Employment Agreement dated November 30, 2025, Mr. Durso's compensation includes:
- Base Salary: $725,000 annually.
- Incentive Compensation: Target annual bonus of 60% of base salary, based on performance goals.
- Equity Grants (Effective Dec 1, 2025):
- 633,700 Restricted Stock Units (RSUs) vesting over four years (25% annually).
- 1,824,400 Stock Options vesting over four years (25% annually, remainder monthly).
- Restrictions: No additional equity awards in Q1 2026 and no base salary increase in 2026.
- Severance Provisions:
- Standard Termination: 12 months of salary and 12 months of COBRA coverage if terminated without Cause or resigns for Good Reason.
- Change in Control: 18 months of salary, 1.5x target bonus, and 18 months of COBRA coverage if termination occurs within two years of a Change in Control.
Risks and Contingencies
Payments and benefits for both executives are contingent upon the execution of a general release of claims and continued compliance with restrictive covenants. The filing notes that the descriptions of the agreements are summaries and are qualified by the full text of the agreements attached as Exhibits 10.1 and 10.2.
Investor Verification Checklist
- Verify the exact vesting schedules and performance criteria for Mr. Durso's equity grants in the full text of Exhibit 10.2.
- Confirm the specific performance metrics required for Dr. Garg to receive his fiscal year 2025 bonus.
- Review the definitions of "Cause" and "Good Reason" in the Durso Agreement to understand severance triggers.
- Check subsequent filings for any updates to the transition timeline or additional executive appointments.